Immuno-Oncology for Solid Tumors: Overcoming Barriers in the Tumor Microenvironment from thescientistllc on Vimeo.
The solid tumor microenvironment is immunosuppressive and poses a significant obstacle to achieving clinical success with various immunotherapies. Most notably, immune checkpoint pathways, including PD-1, PD-L1, and CTLA-4, allow tumors to evade the body’s usual immune reaction, leading to disease progression. Checkpoint blockade via monoclonal antibodies results in augmented T-cell activation and proliferation to enhance the anti-tumor immune response and has revolutionized the field, but not all patients are candidates and severe adverse effects persist. Therefore, the development of other approaches, such as antibody-drug conjugates, vaccines, and adoptive cell-based therapies, has surged. Recent advances in immunotherapy have certainly produced enhanced treatment options for solid tumors, but obstacles to their mainstream use remain. To explore novel strategies in immuno-oncology for solid tumors, The Scientist is bringing together a panel of experts to share their research and...
Topics to be covered:
- Immunotherapy in Lung Cancer
- Adoptive Immunotherapy: Overcoming Barriers Against Solid Tumors with Potent T cells
Meet the Speakers:
Grace Dy, MD
Chief, Thoracic Oncology
Associate Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Chrystal Paulos, PhD
Associate Professor of Microbiology and Immunology
Co-Leader of the Cancer Immunology Program at the Hollings Cancer Center
Endowed Peng Chair of Melanoma in Department of Dermatology and Dermatological Surgery
Medical University of South Carolina, College of Medicine
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
